Business
Sanofi and Regeneron Strike an $8 Billion Deal to Build Dupixent’s Successors
With the $18 billion allergy and eczema blockbuster losing patent protection in 2031, the partners are betting on four long-acting antibodies that hit the same pathways with far fewer injections.